ARCHIVES

Charles Balch resigns as ASCO executive vice president; Joseph Bailes named interim EVP.

This article is from The Cancer Letter archive.

Vol. 31 No. 39 | October 28, 2005

Download PDF Visit The Full Archive

Related Articles

Genentech Move Nixes Hospital Discounts: Avastin, Herceptin, Rituxan Now Sold Under Tighter Control by Drug Maker

October 3, 2014

Novartis Begins Study Of Femara And Zometa In Postmenopausal Early Breast Cancer

December 27, 2002

Obey Accuses Industry Of Blocking Control Of Carcinogens

November 10, 1978

Professional Societes; ASCO’s Strength Is In Its Diversify, Lichtor Says

May 21, 1999

Revlimid Plus Steroid Effective In Clinical Trial

November 30, 2007

CHOP Training Conference Planned

January 23, 1981